TriangleDISEASE & TREATMENT SETTING
KEYTRUDA QLEX: advanced Endometrial Carcinoma with MSI-H stated without a specific alteration after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
KEYTRUDA QLEX, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration (2.1) ] .
Broader topic: Endometrial Cancer
- Source population
- Not part of this definition
- Disease extent
- advanced
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- gene
- MSI-H
- alteration
- stated without a specific alteration
- status
- present
- prior therapy
- class
- following prior systemic therapy in any setting and are not candidates for curative surgery or ra
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for KEYTRUDA QLEX (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- KEYTRUDA QLEX, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration (2.1) ] .
Study evidence for this setting
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice